Pancreatic Cancer Research

ResearcherUniversità Cattolica del Sacro CuoreActive in the last 2 years

Emilio Vicente

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0005-5721-5947; OpenAlex author ID A5110083564, A5110509910. Sources: OpenAlex.

Their work

Papers
15 (first author 0, last author 5)
Trials
0
Grants
0
Labs led
1
Collaborators
35
Papers, trials and grants by year

2013: 3 papers · 2014: 3 papers · 2015: none · 2016: 1 paper · 2017: 2 papers · 2018: none · 2019: 1 paper · 2020: 2 papers · 2021: none · 2022: none · 2023: none · 2024: none · 2025: 1 paper · 2026: 2 papers

Papers 15

  1. A Phase II Trial to Assess the Evolution of the KRAS Mutation Load by Liquid Biopsy in Patients With Resectable Pancreatic Ductal Adenocarcinoma Treated With N… Co-author DOI 10.1097/coc.0000000000001253↗
  2. ASO Visual Abstract: Survival Benefit of Surgery Versus Oncology-Only Therapy in Artery-Involving Borderline Resectable and Locally Advanced Pancreatic Cancer. Co-author DOI 10.1245/s10434-025-18479-z↗
  3. Survival Benefit of Surgery versus Oncology-Only Therapy in Artery-Involving Borderline Resectable and Locally Advanced Pancreatic Cancer. Co-author DOI 10.1245/s10434-025-18212-w↗
  4. A prospective observational study of the clinical and pathological impact of stereotactic body radiotherapy (SBRT) as a neoadjuvant strategy of chemoradiation … Co-author DOI 10.1007/s12094-020-02287-w↗
  5. Prognostic Value of Lymph Node Status for Actual Long-Term Survival in Resected Pancreatic Cancer. Last author PMID 32841360↗
  6. Venous Resection for Locally Advanced Pancreatic Cancer: Time Trend and Outcome Analysis of 65 Consecutive Resections at a High-Volume Center. Last author DOI 10.1016/j.hpb.2022.05.919↗
  7. A comparative study of neoadjuvant treatment with gemcitabine plus nab-paclitaxel versus surgery first for pancreatic adenocarcinoma. Last author DOI 10.1016/j.suronc.2017.08.003↗
  8. Have the current and promising therapeutic options changed the surgeon's role in the treatment of pancreatic cancer? Co-author DOI 10.1590/0100-69912017001012↗
  9. Preoperative treatment with gemcitabine plus nab-paclitaxel is a safe and effective chemotherapy for pancreatic adenocarcinoma. Last author DOI 10.1016/j.ejso.2016.01.006↗
  10. Is arterial infiltration still a criterion for unresectability in pancreatic adenocarcinoma? Co-author DOI 10.1016/j.ciresp.2013.11.001↗
  11. Reply: 'Comments on Stromal disrupting effects of nab-paclitaxel in pancreatic cancer'. Co-author DOI 10.1038/bjc.2014.129↗
  12. Arterial resection for pancreatic cancer: a modern surgeon should change its behavior according to the new therapeutic options. Co-author DOI 10.11138/gchir/2014.35.1.005↗
  13. A preclinical and clinical study of mycophenolate mofetil in pancreatic cancer. Co-author DOI 10.1007/s10637-012-9822-x↗
  14. Stromal disrupting effects of nab-paclitaxel in pancreatic cancer. Co-author DOI 10.1038/bjc.2013.415↗
  15. Alternative arterial reconstruction after extended pancreatectomy. Case report and some considerations of locally advanced pancreatic cancer. Last author DOI 10.6092/1590-8577/1468↗

Closest collaborators

The 25 strongest of 35 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yolanda Quijano · 12 shared papers, 2013–2026 · strength 0.95
  2. Benedetto Ielpo · 8 shared papers, 2013–2026 · strength 0.78
  3. Antonio Cubillo · 6 shared papers, 2013–2026 · strength 0.49
  4. Allegra Ripolli · 2 shared papers, 2025–2026 · strength 0.41
  5. Kongyuan Wei · 2 shared papers, 2025–2026 · strength 0.41
  6. Emanuele F. Kauffmann · 2 shared papers, 2025–2026 · strength 0.41
  7. Riccardo Casadei · 2 shared papers, 2025–2026 · strength 0.41
  8. Sergio Alfieri · 2 shared papers, 2025–2026 · strength 0.41
  9. V. Egorov · 2 shared papers, 2025–2026 · strength 0.41
  10. Gregory G. Tsiotos · 2 shared papers, 2025–2026 · strength 0.41
  11. Alessandro Zerbi · 2 shared papers, 2025–2026 · strength 0.41
  12. Yuichi Nagakawa · 2 shared papers, 2025–2026 · strength 0.41
  13. Niccolò Napoli · 2 shared papers, 2025–2026 · strength 0.41
  14. Elena B. Rangelova · 2 shared papers, 2025–2026 · strength 0.41
  15. Ugo Boggi · 2 shared papers, 2025–2026 · strength 0.41
  16. Marc G. Besselink · 2 shared papers, 2025–2026 · strength 0.41
  17. Giuseppe Fusai · 2 shared papers, 2025–2026 · strength 0.41
  18. Roberto Coppola · 2 shared papers, 2025–2026 · strength 0.41
  19. Riccardo R.C. Caruso · 6 shared papers, 2013–2020 · strength 0.37
  20. Hipólito J. Durán · 6 shared papers, 2013–2020 · strength 0.37
  21. Carlos Plaza Hernandezv · 6 shared papers, 2013–2020 · strength 0.34
  22. Rafael Álvarez-Gallego · 2 shared papers, 2017–2026 · strength 0.31
  23. Berta Laquente · 1 shared paper, 2026 · strength 0.25
  24. Florian Castet · 1 shared paper, 2026 · strength 0.25
  25. Juli Busquets · 1 shared paper, 2026 · strength 0.25

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.